Literature DB >> 10879679

Multidrug resistance increment in a human colon carcinoma cell line by colchicine.

M J Ruiz Gómez1, L Gil, A Souviron, M Martínez Morillo.   

Abstract

The most important mechanism in drug resistance is the multidrug resistance (MDR) phenomenon. It is possible to select MDR cells by in vitro exposure to cytotoxic agents. The resistance is due to the hyperexpression of the P-glycoprotein (P-Gp) that take drugs out from the cells. In this study, a colchicine resistant subline (HCA-2/1cch) was selected from a human colon adenocarcinoma after a short period of drug exposure, as an in vitro model of drug resistance selection. These cells showed cross-resistance to other drugs, which were not present in the medium during selection. The relative resistance was 3.32 for colchicine, 3.15 for vinblastine, 2.62 for vincristine and 5.22 for mitomycin C. P-glycoprotein levels were assayed by flow cytometry. It was found that a significant increase of 2.35 and 1.59 had occurred in the peak and mean channel of fluorescence, respectively, indicating an increment of P-glycoprotein expression in relation to the parental line. Moreover, verapamil (10 microg/ml) produced a partial reversion of multidrug resistance. The sensitisation rates were 7.41 for colchicine, 1.25 for vinblastine, 2.36 for vincristine and 1.17 for mitomycin C. The data obtained suggest that colchicine exposure period (10 weeks) and dose (0.5 microg/ml) assayed were sufficient to produce an increment in multidrug resistance. This resistance could be due to higher level of P-Gp expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879679     DOI: 10.1007/BF03179774

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  19 in total

1.  Establishment of tumor cell lines from a patient with head and neck cancer and their different sensitivities to anti-cancer agents.

Authors:  S Komiyama; K Matsui; S Kudoh; I Nogae; Y Kuratomi; Y Saburi; K Asoh; K Kohno; M Kuwano
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

2.  Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA.

Authors:  R NicAmhlaoibh; M Heenan; I Cleary; S Touhey; C O'Loughlin; C Daly; G Nuñez; K J Scanlon; M Clynes
Journal:  Int J Cancer       Date:  1999-07-30       Impact factor: 7.396

3.  Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells.

Authors:  J F Lemontt; M Azzaria; P Gros
Journal:  Cancer Res       Date:  1988-11-15       Impact factor: 12.701

4.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.

Authors:  V Höllt; M Kouba; M Dietel; G Vogt
Journal:  Biochem Pharmacol       Date:  1992-06-23       Impact factor: 5.858

Review 5.  Genetic aspects of multidrug resistance.

Authors:  J L Biedler
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

6.  Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells.

Authors:  L S Kirschner; L M Greenberger; S I Hsu; C P Yang; D Cohen; R L Piekarz; G Castillo; E K Han; L J Yu; S B Horwitz
Journal:  Biochem Pharmacol       Date:  1992-01-09       Impact factor: 5.858

7.  Development of tumour cell resistance to tumour necrosis factor does not confer resistance to cytotoxic drugs.

Authors:  M L Neale; N Matthews
Journal:  Eur J Cancer Clin Oncol       Date:  1989-01

8.  Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein.

Authors:  R J Arceci; K Stieglitz; J Bras; A Schinkel; F Baas; J Croop
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

9.  Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.

Authors:  P Nygren; R Larsson
Journal:  Biosci Rep       Date:  1990-04       Impact factor: 3.840

10.  Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).

Authors:  P R Twentyman; J G Reeve; G Koch; K A Wright
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more
  5 in total

1.  Verapamil sensitisation to alkaloids on colchicine-selected human colon adenocarcinoma cells.

Authors:  M J Ruiz Gómez; A Souviron; L Gil; M Martínez Morillo
Journal:  J Physiol Biochem       Date:  2001-12       Impact factor: 4.158

2.  P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine.

Authors:  M J Ruiz-Gómez; A Souviron; M Martínez-Morillo; L Gil
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

3.  Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Authors:  Rozanne Arulanandam; Cory Batenchuk; Oliver Varette; Chadi Zakaria; Vanessa Garcia; Nicole E Forbes; Colin Davis; Ramya Krishnan; Raunak Karmacharya; Julie Cox; Anisha Sinha; Andrew Babawy; Katherine Waite; Erica Weinstein; Theresa Falls; Andrew Chen; Jeff Hamill; Naomi De Silva; David P Conrad; Harold Atkins; Kenneth Garson; Carolina Ilkow; Mads Kærn; Barbara Vanderhyden; Nahum Sonenberg; Tommy Alain; Fabrice Le Boeuf; John C Bell; Jean-Simon Diallo
Journal:  Nat Commun       Date:  2015-03-30       Impact factor: 14.919

4.  Proteomic analysis of the low mutation rate of diploid male gametes induced by colchicine in Ginkgo biloba L.

Authors:  Nina Yang; Yuhan Sun; Yaru Wang; Cui Long; Yingyue Li; Yun Li
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

5.  Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum.

Authors:  Lin Du; Andrew J Robles; Jarrod B King; Susan L Mooberry; Robert H Cichewicz
Journal:  J Nat Prod       Date:  2014-06-03       Impact factor: 4.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.